These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7954404)

  • 1. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
    He J; Allen JR; Collins VP; Allalunis-Turner MJ; Godbout R; Day RS; James CD
    Cancer Res; 1994 Nov; 54(22):5804-7. PubMed ID: 7954404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
    Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines.
    He J; Olson JJ; James CD
    Cancer Res; 1995 Nov; 55(21):4833-6. PubMed ID: 7585516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells.
    Srivenugopal KS; Ali-Osman F
    Oncogene; 1996 May; 12(9):2029-34. PubMed ID: 8649864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
    Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
    J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of P16INK4 expression is frequent in high grade gliomas.
    Nishikawa R; Furnari FB; Lin H; Arap W; Berger MS; Cavenee WK; Su Huang HJ
    Cancer Res; 1995 May; 55(9):1941-5. PubMed ID: 7728764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
    Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
    Zariwala M; Liu E; Xiong Y
    Oncogene; 1996 Jan; 12(2):451-5. PubMed ID: 8570224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
    Wang Y; Becker D
    Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.
    Arap W; Nishikawa R; Furnari FB; Cavenee WK; Huang HJ
    Cancer Res; 1995 Mar; 55(6):1351-4. PubMed ID: 7882335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletions of the p16 gene in pediatric leukemia and corresponding cell lines.
    Kees UR; Ranford PR; Hatzis M
    Oncogene; 1996 May; 12(10):2235-9. PubMed ID: 8668350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines.
    Igaki H; Sasaki H; Kishi T; Sakamoto H; Tachimori Y; Kato H; Watanabe H; Sugimura T; Terada M
    Biochem Biophys Res Commun; 1994 Sep; 203(2):1090-5. PubMed ID: 8093026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Loss of CDKN2 gene and amplification of cyclin D1 gene in human esophageal cancer].
    Zheng J; Hou P; Zhou C
    Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):408-11. PubMed ID: 9387288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
    Zariwala M; Xiong Y
    Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas.
    Tenan M; Benedetti S; Finocchiaro G
    Biochem Biophys Res Commun; 1995 Dec; 217(1):195-202. PubMed ID: 8526910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
    Fujishita T; Mizushima Y; Kashii T; Kobayashi M
    Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transformation of human glioma cell lines with the p16 gene inhibits cell proliferation.
    Hama S; Sadatomo T; Yoshioka H; Kurisu K; Tahara E; Naruse I; Heike Y; Saijo N
    Anticancer Res; 1997; 17(3C):1933-8. PubMed ID: 9216647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
    Schutte M; Hruban RH; Geradts J; Maynard R; Hilgers W; Rabindran SK; Moskaluk CA; Hahn SA; Schwarte-Waldhoff I; Schmiegel W; Baylin SB; Kern SE; Herman JG
    Cancer Res; 1997 Aug; 57(15):3126-30. PubMed ID: 9242437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.